MKM Partner Raises Price Target on Pfizer (PFE)

Article Stock Quotes (1) Comments (0)

MKM Partners maintained a Buy on Pfizer (NYSE: PFE) and increased its price target to $29.00 (from $27.00).

"Our price target is based on what we consider to be a fair multiple, parity with the group 2013E multiple of 12.7x applied to 2013E PFE earnings of $2.26. Our target price is based on our 3D valuation framework. Pfizer scores below average on its 2012E-2016E pipeline and has the least patent exposure and a slightly below-average score on company-specific factors," said analyst Jon LeCroy, M.D.

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $25.35 yesterday, with a 52 week range of $17.39-$25.47.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Citi Raises PT on Micron Technology (MU) to $19
• Price Stability for Micron (MU) Means a Higher Stock Price - Jefferies
• Wells Fargo Upgrades ProLogis (PLD) to Outperform

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?